Anne Katrin Hilbert - Concepedia

Concepedia

Author

Anne Katrin Hilbert

Novartis (Italy)

Also Known As

A Hilbert, A K Hilbert, A. Hilbert, A.K Hilbert, Anne Hilbert, Anne K. Hilbert, Anne Katrin Hilbert

20

Publications

1.3K

Citations

14

H-Index

28

Concepts

All Affiliations

Novartis (Italy)Novartis (Germany)Newron Pharmaceuticals (Italy)Novartis (United States)Novartis (Switzerland)

AK

About

Anne Katrin Hilbert is an author at Novartis (Italy) specializing in vaccination, medicine, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	708
2	Engineering	1	1	16
3	Public Health	1	1	17
4	Allergy	1	1	193
5	Biomedical Engineering	1	1	16

Anne Katrin Hilbert

×

13

Publications

1.3K

Citations

13

H-Index

	Year	Citations
MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines Surender Khurana, Nitin Verma, Jonathan W. Yewdell, Science Translational Medicine	2011	344
Adjuvanted H5N1 vaccine induces early CD4<sup>+</sup>T cell response that predicts long-term persistence of protective antibody levels Grazia Galli, Duccio Medini, Erica Borgogni, Proceedings of the National Academy of Sciences VaccinationVaccinologyAvian InfluenzaProtective Antibody LevelsVaccine Research	2009	257
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice Andreas Wack, Barbara C. Baudner, Anne Katrin Hilbert, Vaccine VaccinationCross-protectionLong-lasting AntibodyVaccine DevelopmentAllergy	2008	193
Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy Adults Pierre Van Damme, Froukje Kafeja, Alessandra Anemona, PLoS ONE	2011	89
Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture Agnieszka Szymczakiewicz‐Multanowska, Nicola Groth, Roberto Bugarini, The Journal of Infectious Diseases	2009	80
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial Wendy A. Keitel, Nicola Groth, Maria Lattanzi, Vaccine VaccinationPhase 1/2Cross-protectionVaccine DevelopmentImmunology	2009	72
Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses Isabella Alberini, Elena Del Tordello, Alba Fasolo, Vaccine VaccinationH5n1 Influenza VirusesCross-protectionViral DiagnosticsReliable Assay	2009	66
Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer Olaf Zent, Angelika Banzhoff, Anne Katrin Hilbert, Vaccine VaccinologyVaccine SafetyVaccinationVaccine DevelopmentVaccine Surveillance	2003	66
Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age Timo Vesikari, Stan L. Block, Fernando Guerra, The Pediatric Infectious Disease Journal	2012	40
Safety and Immunogenicity of a New Fully Liquid DTPw-HepB-Hib Combination Vaccine in Infants G Kanra, Ateş Kara, Okan Demiralp, Human Vaccines	2006	34

Page 1